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CD44v8-10 as a potential 
theranostic biomarker for targeting 
disseminated cancer cells in 
advanced gastric cancer
Eun-Seok Choi1,3, Hyunjin Kim2, Hyung-Pyo Kim3, Yongdoo Choi1,2 & Sung-Ho Goh1
Gastric cancer is the third most common cause of cancer mortality, and the survival rate of stage IV 
advanced gastric cancer (AGC) patients with distant metastasis is very low. Thus, the detection and 
eradication of disseminated cancer cells by targeting cell surface molecules in AGC would improve 
patient survival. The hyaluronic acid receptor, CD44, has various isoforms generated by alternative 
splicing, and some isoforms are known to be correlated to gastric cancer. In this study, to find out the 
most appropriate CD44v for targeting AGC, we analysed the expression differences of CD44 isoforms 
at the mRNA level in stomach cancer cell lines as well as in 74 patients with AGC by using exon-specific 
qRT-PCR. Among the CD44v isoforms, CD44v8-10 was determined as the most promising biomarker 
for the development of theranostic agents of gastric cancer. Next, we synthesised the conjugate of 
anti-CD44v9 antibody with near-infrared fluorophore or photosensitiser, and then demonstrated its 
feasibility for target cell-specific imaging and photoimmunotherapy in gastric cancer. As a result, these 
conjugates have clearly demarcated the surface of CD44v8-10 expressing cancer cells and showed 
efficient phototoxic effects. Therefore, this study revealed that CD44v8-10 is the efficient theranostic 
biomarker to target disseminated cancer cells in AGC.
Stomach cancer is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the 
total). In particular, the highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 
100,000 in women)1. Thus, it is necessary to develop a therapeutic strategy to overcome the high mortality rates 
caused by stomach cancer. Stomach cancer is composed of heterogeneous cell populations that manifest malig-
nancy by aberrantly regulating cell proliferation, differentiation, angiogenesis, migration, and metastasis2, and its 
carcinogenic process is complex3, 4. To obtain a comprehensive understanding of the pathophysiological status of 
cancer at a molecular level, an enormous amount of genome data is being profiled and analysed worldwide, but 
the only approved biomarker of tumour response to targeted agents in advanced gastric cancer (AGC) is human 
epidermal growth receptor (HER)-2. Although trastuzumab is an approved targeted therapeutic drug for the sub-
group of (HER)-2-positive AGC, based on the results of a ToGA trial (phase III trastuzumab for gastric cancer), 
the majority of patients did not respond in the first-line setting. Therefore, identification of new biomarkers for 
detection and therapy of gastric cancer is an ongoing clinical challenge.
The single-pass transmembrane glycoprotein CD44, which binds to hyaluronic acid, has also been recognized 
as one of the markers to fit the purpose. It is implicated in tumour cell invasion and metastasis5, as well as many 
physiological phenomena related to tumour formation including cell migration, invasion, and metastasis6. The 
CD44 gene has ten constant exons and ten variable exons (v1-v10) placed between exon 5 and 16, and multi-
ple isoforms of CD44 molecules are generated via alternative mRNA splicing of the ten variable exons. While 
the standard isoform of CD44 (CD44s) is known to predominate in hematopoietic cells and normal epithelial 
cell subsets, many variant isoforms (CD44v) with the extended extracellular stalk region are more prevalent in 
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epithelial carcinomas7. It was reported that the CD44v3,8-10 isoform was involved in the metastasis of breast 
cancer8 and colorectal adenomas9, and CD44v3 and CD44v6 for colorectal cancer10. Furthermore, CD44v6 
and CD44v9 interact with CD95, the death receptor, interfering with death receptor signalling and inhibiting 
apoptosis11.
Although the roles of CD44v in cancer stem cells (CSCs) remain elusive, it was reported that CD44(+) gastric 
cancer cells have the stem cell properties of self-regeneration and the ability to form differentiated programs 
when compared with CD44(−) cells12. Thus, CD44 variants might also be considered as susceptible targets for 
cancer stem cells13; however, this has not yet been confirmed2. Relapse of gastric cancer has been debated in terms 
of stem cell-like properties of cells in the lesions, and CD44v914 and CD44v8-10 isoforms12, 15 were suggested as 
predictive markers as well as molecules for targeting CSCs. In addition, CD44v8-10, which interacts with and 
thereby stabilizes xCT at the plasma membrane, was reported as the key component contributing to reactive oxy-
gen species (ROS) defence through upregulation of the synthesis of reduced glutathione (GSH)5, 16.
In addition, based on the idea that the binding between CD44 and sodium hyaluronate is mediated by 
many different intra/extracellular signalling pathways and is related to cancer proliferation and tumorigene-
sis17, clinical trials of antibody-mediated therapeutics are developed. Recently, Birzele et al.18 reported a CD44 
blocking antibody, RG7356, which binds a constant region of the CD44 molecule, and it showed relevance for 
CD44s-expressing tumour cells. However, the suggested CD44v isoforms have not been screened and validated 
among patients yet.
Here, we analysed the differential expression of CD44v at the mRNA level in patients with AGC and com-
pared the results with the expression of standard CD44s. Based on the differences in CD44v profiles, we also 
investigated the CD44v8-10 isoform as a new therapeutic target for disseminated cancer cells in AGC. Finally, 
we showed that conjugates of anti-CD44v9 antibody with near-infrared fluorophore or photosensitiser may have 
potential for specific imaging and photoimmunotherapy of gastric cancer.
Results
Differential expression of CD44 alternative spliced variants in gastric cancer cell lines and gas-
tric cancer patient tissues. From the previous study of profiling exon usage differences between normal 
and tumour tissues of 30 patients with early gastric cancer by using Affymetrix Exon 1.0ST array (GSE30727), 
we found CD44v to be a gene which shows significant differences in alternative splicing (p-value = 2.75 × 10−3) 
as well as in expression (p – value = 1.97 × 10−4) at the mRNA level. To validate this result in a separate sample 
set, we designed FAM-TAMRA TaqMan probes spanning the junction of alternative spliced exons and primer 
pairs specific for alternative splice variants of CD44s, CD44v6-10, CD44v8-10 and CD44v3,8-10 (Fig. 1A and 
Supplementary Table S1) as these are frequently reported splice variants in cancers.
First, we screened the variants using qRT-PCR in 19 cell lines and tissues from 74 patients with gastric cancer. 
The absolute quantification of four types of CD44 expression variants revealed that CD44v8-10 was the major 
isoform in gastric cancer cell lines except for MKN-28 (Fig. 1B). CD44s was the second most abundant species, 
but its expression was not prominent. The expression of CD44v6-10 or CD44v3,8-10 was also detected in gastric 
cancer cells but it was very low. In comparison, CD44s was the major isoform at the mRNA level in non-gastric 
cancer cell lines though some cell lines such as JIMT-1 showed CD44v8-10 as the major isoform (Fig. 1B). In 
non-cancer cell lines including HDF, HMEC, and HEK-293, the overall CD44 expression itself was much lower 
than that in cancer cell lines, and the level of alternative splice variant isoforms was not significantly higher than 
that of CD44s (Fig. 1B). When we analysed the CD44 variant expression in normal tumour-paired tissues from 
patients with gastric cancer (Table 1), CD44s and CD44v6-10 were detected in all normal and tumour tissues 
(f = 1.000), and CD44v8-10 was detected in 71 out of 74 normal tissues (f = 0.959) and 73 out of 74 tumour tissues 
(f = 0.986). In accordance with gastric cancer cell lines, CD44v8-10 was the most highly expressed form followed 
by CD44s (Fig. 1C). These results suggest that the CD44v8-10 splice variant is the major CD44 isoform in gastric 
cancer and its expression in tumours is much higher than that of other variants. Thus, CD44v8-10 can be used as 
a potential target for gastric cancer-specific therapies.
Anti-CD44v9 antibody conjugated with near-infrared (NIR) fluorophore recognizes the 
CD44v8-10 expressing cells in tumours. To confirm whether the protein level of CD44v8-10 is also 
elevated in tumour tissues, we performed immunohistochemistry using CD44 variable exon 9 specific antibody 
(RV3) on patients with high CD44v8-10 expression in tissue samples. In normal tissue, protein expression of the 
exon v8-10-containing CD44 variant was not detected except for specific regions such as endothelial cells of gas-
tric glands. On the contrary, in tumour tissues, CD44v8-10 protein expression was observed in almost the entire 
region and was prominent in the region of dysplastic tissue (Fig. 2A). Therefore, it is suggested that the CD44v8-
10 variant can be used to target gastric tumour tissues for imaging and therapy.
Next, we checked the feasibility of targeting the CD44v8-10 on fresh three-dimensional tissue samples using 
NIR fluorophore-conjugated anti-CD44v9 antibody. The same pairs of gastric cancer patient tissue samples 
that were used for immunohistochemistry were treated with ATTO680 fluorophore-conjugated anti-CD44v9 
antibody, and the results were imaged with an in vivo imaging instrument (IVIS Lumina XR, Xenogen 
Corporation-Caliper, CA, USA, ex. 660/20, em. 710/40 nm). ATTO680 is a water-soluble NIR fluorophore 
and has a good fluorescence quantum yield in water (ΦF = 0.19)19. Notably, the strongest fluorescence signal 
was observed in the tumour tissues as compared with that of normal tissues (Fig. 2B). These results suggest 
that NIR fluorophore-conjugated anti-CD44v9 antibody preferentially binds to the three-dimensional tumour 
mass expressing CD44v8-10 variant protein and therefore may be used for selective imaging of CD44v8-
10-overexpressing gastric cancers.
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Establishment of the CD44v8-10 variant expressing cell line. To quantify the CD44 molecules on 
the cell surface, we performed immunocytochemistry of three gastric cancer cells (MKN-28, KATO-III, and 
SNU-638) and normal cells (HDF) to compare the protein expression with the expression level of mRNA. As 
expected, MKN-28 showed no signals on the membrane and the other three cell lines followed the expression 
patterns of mRNA. HDF and KATO-III have highly expressed CD44s and CD44v8-10, respectively, and SNU-638 
expressed both CD44s and CD44v8-10 (Supplementary Fig. 1).
To test the efficacy of antibody-based targeting CD44v8-10, we set up cell lines that express only CD44s 
or CD44v8-10 by using the MKN-28 cell line. This line does not express CD44 due to hyper-methylation of 
the CD44 promoter region20. We first verified the expression of GFP-tagged CD44 variants by flow cytometry 
(Fig. 3A). MKN-28 was negative for fluorescence and all the other stable cell lines harbouring GFP or GFP-tagged 
CD44 showed green fluorescence. To confirm the expression of different CD44 variants, we quantified absolute 
mRNA expression by qRT-PCR. Measuring the levels of CD44s or CD44v8-10 variant in each stable cell line 
showed that each cell line expressed its own CD44 species exclusively (Fig. 3B). The expression of CD44 pro-
teins in each cell line was confirmed by western blot. As expected, pan-CD44 antibody detects both CD44s and 
CD44v8-10, but anti-CD44v9 antibody only detects CD44v8-10 in stable cell lines (Fig. 3C). Finally, we observed 
the expression of CD44 variants on the membranes of the stable cell lines via an immunocytochemistry assay 
(Fig. 3D). Western blotting revealed that the pan-CD44 antibody detects both CD44s and CD44v8-10 expression 
in MKN-28 cells, but anti-CD44v9 antibody detects only cells that express CD44v8-10.
Figure 1. (A) Structure of human CD44 pre-mRNA and its alternative splice variants. To detect alternative 
splice variants, CD44s or CD44v specific TaqMan probes spanning the border of contiguous exons and primer 
pairs were applied. (B) The comparison of mRNA expression levels of CD44s and CD44v in the cell lines 
measured by absolute quantification of qRT-PCR. (C) The comparison of mRNA expression level of CD44s and 
CD44v between normal and tumour tissue of stomach cancer patients (n = 74).
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Specificity of NIR fluorophore-conjugated anti-CD44v9 antibody for targeting CD44v8-10 
expressing cells. It is often difficult to discriminate or detect tumour margins or disseminated peritoneal 
micrometastatic gastric tumours during a surgical operation. Therefore, development of target cell-specific imag-
ing probes for gastric cancer cells is a current clinical challenge. To establish the CD44v8-10-specific diagnos-
tics, we conjugated the anti-CD44v9 antibody with NIR fluorophore ATTO680 (CD44v9-ATTO680), and then 
checked whether this conjugate could specifically bind to gastric cancer cells with CD44v8-10 overexpression.
To verify the CD44v8-10-specific binding of the conjugated antibody on the cell surface, we treated 
CD44v9-ATTO680 to CD44(−) MKN-28, MKN-28 transfected with mock vector, CD44s expressing MKN-28, 
and CD44v8-10 variant stable MKN-28 cell lines as well as with CD44(−) HDF cells and two CD44v8-10(+) gas-
tric cancer cells (KATO-III and SNU-638) (Fig. 4). As expected from the qRT-PCR results, MKN-28 cells without 
CD44v8-10 expression did not show any detectable fluorescence signal on the cell surface. We observed that the 
anti-CD44v9-ATTO680 conjugate recognises the cells with high expression of CD44v8-10 (KATO-III and SNU-
638) and the CD44v8-10 stable MKN-28 cell line (Fig. 4).
Ta r g e t e d  p h o t o i m m u n o t h e r a p y  o f  C D 4 4 v 8 - 1 0  e x p r e s s i n g  c e l l s  b y  u s i n g 
anti-CD44v9-photosensitiser conjugate. Methylene blue (MB), an FDA-approved NIR fluorophore, 
has long been used for NIR fluorescence imaging in clinics. In addition, its use in photodynamic therapy (PDT) 
of cancers has been exploited. That is, laser exposure to this dye causes not only NIR fluorescence (fluorescence 
quantum yield, ΦF = 0.053)21 but also the highly efficient generation of singlet oxygen (singlet oxygen quantum 
yield, ΦΔ = 0.49)22, thereby selectively killing cancer cells23. To examine whether the MB conjugated anti-CD44v9 
antibody could specifically recognise only CD44v8-10 expressing cells among CD44v8-10(−) cells, we treated it 
in two combinations. The first combination was CD44(−) normal HDF and MKN-28 cells transfected with mock 
vector (Fig. 5A). The second combination was CD44(−) MKN-28 and CD44v8-10(+) MKN-28 cells (Fig. 5B). 
Cells were treated with propidium iodide (PI) before and after light irradiation to analyse damage to cell mem-
branes. The results showed no detectable CD44v9-MB fluorescence or PI staining in the CD44(−) HDF/MKN-28 
transfected with mock vector mixed condition before and after 633-nm laser irradiation (Fig. 5A). In contrast, 
Fig. 5B showed specific binding of CD44v9-MB conjugate to CD44v8-10(+) MKN-28 even when combined with 
CD44(−) MKN-28 cells, and subsequent light irradiation-induced selective cell damage of the conjugate-bound 
CD44v8-10(+) MKN-28 cells. These results suggest the applicability of anti-CD44v9-MB antibody conjugate 
No. of patients
Number of patients
Total 74
Male 52
Female 22
Age at diagnosis (yrs)
Range 21–86
Mean ± SD 60.7 ± 13.3
Disease stage†
Tumor stage
T1a 0
T1b 1
T2 16
T3 29
T4a 22
T4b 6
Node stage
N0 26
N1 11
N2 13
N3a 16
N3b 8
Metastasis stage
M0 63
M1 11
Lauren type
Intestinal 33
Diffuse 24
Mixed 7
Intermediate 8
Not annotated 2
Borrmann type
Type I (protruded type) 1
Type II (ulcerative type) 21
Type III (ulceroinfiltrated type) 45
Type IV (diffuse type) 6
Not determined 1
Table 1. Clinicopathological information of 74 advanced gastric cancer patients. †Stage classification follows 
the TNM classification system by International Union Against Cancer (UICC).
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for NIR fluorescence detection and photoimmunotherapy of both primary gastric cancer cells and disseminated 
cancer stem cell-like CD44v8-10(+) cells in the peritoneal cavity in AGC.
Discussion
The survival prospects of many patients with AGC are not hopeful because most of them suffer from relapses 
caused by distant metastasis. The most common sites to which cancer cells spread are the liver, peritoneum, and 
distant lymph nodes. Among these distant metastases in AGC, peritoneal dissemination is more frequently asso-
ciated with death from AGC (53–60%) than hepatic metastases (~40%)24. The 5-year survival rate with metachro-
nous peritoneal carcinomatosis was reported as only 3%25. Therefore, it is imperative that adequate treatment 
is received to eradicate cancer cells seeded into the abdominal cavity in order to improve disease-free survival 
in patients with gastric cancer. Recently, a few intraperitoneal immunotherapies using catumaxomab targeting 
epithelial cell adhesion molecule (EpCAM) antigen combined with cytoreductive surgery (CRS) or hyperther-
mic intraperitoneal chemotherapy (HIPEC) were reported to significantly increase the survival of patients26, 27. 
However, targeting a more cancer cell-specific antigen was not applied. Thus, it is crucial to understand the patho-
physiological states of stomach cancer at a molecular level to develop targeted therapeutics as well as identify 
biomarkers for the diagnosis of distant metastasis. Notably, an enormous amount of data from The Cancer Atlas 
Genome (TCGA) project is being generated and analysed to reveal targeting opportunities28. Many biomarkers 
of gastric cancer have been identified and therapeutic biomarkers are being used as potential targets of cancer 
therapy, but lack accurate clinical evidences because the range of molecular characteristics of gastric cancer is 
wide depend on studies (7–44%)29.
Figure 2. (A) Immunohistochemistry of normal-tumour paired gastric cancer tissue using anti-CD44v9 
antibody. Normal tissue showed no CD44v9 signals in the section and has regularly arranged gastric ducts. 
In comparison, the CD44v9 signal is prevalent in tumour tissue and it has dysplastic phenotypes at the ductal 
regions. (B) Immunofluorescence stained images with tissue sample obtained from a gastric cancer patient 
using anti-CD44v9-ATTO680.
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In this study, we focused on the CD44 molecule, the hyaluronic acid receptor that has several valuable clin-
ical significances. It is known that CD44, especially CD44v isoforms, is highly expressed in cancers, and the 
expression of CD44v isoforms is differential among cancer species30. Recently, CD44 has been recognized as a 
cell surface marker for cancer initiating cells16, 31, and correlations between isoform and cancer stem cells were 
reported in breast cancer32, prostate cancer33, colorectal cancer34, and primary lung cancer35. In gastric cancer, 
relapse of gastric cancer has been debated in terms of stem cell-like properties of cells in the lesions and CD44v8-
10 has been reported as the cancer stem cell marker in gastric cancer15. It was reported that CD44 has the ability 
to cause peritoneal dissemination in gastric cancer36. Therefore, according to these reports, CD44v is a promising 
therapeutic target to eliminate the peritoneal disseminated cancer stem cells in gastric cancer. In this study, we 
confirmed CD44v8-10 is the major isoform of the CD44 variants in AGC (Fig. 1). The anti-CD44v9 antibody 
used in this study could detect CD44v6-10 and CD44v3,8-10 as well, because the v9 exon is also included in these 
variants. However, as shown in Fig. 1B and C, the expression level of CD44v8-10 mRNA is considerably higher 
than that of the other two variants in both gastric cancer cell lines and tumour tissues. In particular, CD44v3,8-
10 is rarely expressed. These differences would imply that CD44v8-10 is predominantly detected rather than 
CD44v6-10 or CD44v3,8-10. The expression of CD44s in tumour tissue is prominent because human tissue does 
Figure 3. Establishment of stably CD44s and CD44v8-10expressing cells. (A) Stable expression of GFP-tagging 
open reading frame was confirmed by flow cytometry. (B) Expression of the stably expressed CD44s and 
CD44v8-10 was confirmed at mRNA level by qRT-PCR. (C) Protein level was confirmed by western blot using 
pan-CD44 antibody and CD44v9 antibody. (D) The location of CD44s and CD44v8-10 on MKN-28 cells was 
also confirmed by immunocytochemistry.
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Figure 4. Specificity of ATTO680-conjugated anti-CD44v9 antibody on CD44v8-10(−) or (+) cells confirmed 
by NIR fluorescence image. No fluorescent signal was detected in MKN-28 cells, mock vector transfected MKN-
28 cells, CD44s transfected MKN-28 cells, and HDF cells. The CD44v8-10 expressing MKN-28 cells, SNU-638 
and KATOIII cells, clearly showed fluorescence on the lining of the cell membrane. Scale bar indicates 20 μm.
Figure 5. Targeted photoimmunotherapy of CD44v8-10(+) cancer cells using anti-CD44v9-MB conjugate. 
Results obtained with CD44(−) HDF/CD44(−) Mock MKN-28 cell combination (A) and CD44(−) MKN-
28/CD44v8-10(+) MKN-28 cell combination (B). Cells were treated with anti-CD44v9-MB conjugate 
(8.96 μg/0.3 mL, 0.2 μM MB equivalent) for 1 h, and then the cells were irradiated with 633-nm laser light. Scale 
bar indicates 20 μm.
www.nature.com/scientificreports/
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not consist of pure cancer cells, but also contains haematopoietic cells, fibroblasts, and stromal cells that express 
CD44s. As shown in Fig. S1, the fibroblast cell, HDF, shows no signal upon CD44v9 antibody treatment, but 
shows a high signal in response to the pan-CD44 antibody. This result coincides with the RT-PCR result shown in 
Fig. 1B. Therefore, targeting CD44v8-10 is considerably more efficient than targeting CD44s to eliminate cancer 
cells from a heterogeneous cell population. In addition, some M1 patients showed substantially higher levels of 
CD44v8-10/CD44s than M0 patients did. This is in contrast to the CD44v6-10/CD44s levels, which were similar 
in both the groups (Supplementary Fig. S3). Of note, the gastric cancer cell lines originating from metastasized 
region (SNU-216) or ascites (SNU-638) definitely also showed higher CD44v8-10 levels than the cell lines from 
primary sites (AGS) did. Thus, we can conclude that the conjugates of anti-CD44v9 antibody with NIR fluoro-
phore (ATTO680) or photosensitizer (MB) have potential usefulness for targeted imaging or therapy of advanced 
gastric cancer.
Photoimmunotherapy is a new cancer treatment modality that combines cancer specific antibod-
ies, photosensitisers, and NIR light to selectively kill target cancer cells. Recently Sato et al. developed 
photosensitiser-trastuzumab conjugates and showed their potential for fluorescence imaging and phototherapy 
in the disseminated peritoneal carcinomatosis animal model of HER2-overexpressing gastric cancer37. Thus, we 
examined the idea that photosensitiser-conjugated anti-CD44v9 antibody could be used as a theranostic agent 
for selective detection and therapy of gastric cancers. Therefore, we examined the significance of CD44v8-10 as 
a major target for disseminated gastric cancer. Based on the CD44(−) and CD44v8-10 expressing cell lines, we 
conducted controlled experiments to analyse the therapeutic efficacy of photosensitiser-conjugated anti-CD44v9 
antibody. The CD44v8-10 targeting antibody was conjugated with methylene blue, which has been used in 
photodynamic therapy due to the generation of singlet oxygen when it absorbs NIR light23. We confirmed the 
anti-CD44v9-MB antibody specifically binds only to CD44v8-10-expressing cells, even when those cells are 
mixed with non-CD44v8-10(+) cells. It is worth noting that the cytotoxic effect was turned on only after laser 
exposure (Fig. 5). In addition, it is also noteworthy that, as shown in Figs 2 and 4, the NIR fluorophore (i.e., 
ATTO680)-conjugated anti-CD44v9 antibody showed its potential for specific NIR fluorescence detection of 
CD44v8-10 expressing cells in the in vitro cell and ex vivo tumour-tissue studies. Thus, it could be applied to 
image guided surgery to resect micro tumour masses that are difficult to discriminate with the naked eye. In addi-
tion, CD44v8-10 was reported as the key component contributing to ROS defence through upregulation of the 
synthesis of reduced glutathione (GSH)5, 16. Thus, selective targeting of CD44v8-10-positive cancer cells by PDT 
has a greater translational advantage than targeting a constant region of CD44, such as RG735618, which is also 
expressed ubiquitously on stromal and fibroblast cells, although it is higher in cancer cells.
In this study, we analysed the differential expression of CD44v at the mRNA level in patients with AGC and 
compared this with the expression of standard CD44s. Based on differences in the CD44v profile, we demonstrated 
that the CD44v8-10 isoform is a potential therapeutic target using NIR fluorophore or photosensitiser-conjugated 
anti-CD44v9 antibody. Taken together, these results suggest that targeting the CD44v8-10 isoform will pro-
vide new therapeutic strategies to increase the disease-free survival rates of patients with AGC by eradicating 
metastasis.
Methods
Cell lines and patient stomach tissues. Cell lines were obtained from ATCC (USA) (MKN-28, AGS, 
KATOIII, HCT-116, MDA-231, SK-BR-3, JIMT-1, U87MG, A549, CEM-119, HeLa, Jurkat and HDF) and from 
Korean Cell Line Bank (Seoul National University, Korea) (SNU-216, SNU-638, SNU-719, and SNU-C5) were 
cultured with designated media supplemented with 10% fetal bovine serum and 1x penicillin-streptomycin at 
37 °C 5% CO2 incubator. Human stomach cancer tissues and peri-tumoral normal counter parts were excised 
within 10 min from the gastrectomy, and preserved in RNAlater solution until RNA purification at 4 °C. All 
patients provided informed consent prior to collection of tissues, and all methods were performed in accordance 
with the relevant guidelines and regulations approved by the Institutional Review Board of National Cancer 
Center of Korea (NCCNCS13732).
Preparation of total RNA and cDNA synthesis. Total RNA from patient tissue was extracted using 
Trizol reagent (Thermo Fisher Scientific, USA) and then purified with RNeasy column with DNaseI (Qiagen) 
digestion to remove residual genomic DNA. Two microgram of total RNA primed with poly-d(T)18–20 primer was 
synthesized to first strand cDNA using Transcriptor cDNA synthesis kit (Roche, Switzerland).
Quantitative real-time Polymerase Chain Reaction. The oligonucleotide primers to planking CD44 
variable exons and TaqMan probes that are anchor on the border of linked exons were designed (Fig. 1). 10 ng 
of cDNA used for each amplification of each CD44v with 5 pmoles of each forward and reverse primers and 10 
pmoles of FAM-TAMRA labelled oligonucleotide primers (Bioneer, Korea), and 1x TaqMan master mix (Roche, 
Switzerland) in 10 ul reaction mixture. All the amplifications were carried out triplicate in LightCycler LC480 
Realtime PCR system (Roche, Switzerland) with 45 cycles of thermal cycles of 94 °C for 10 sec and 60 °C for 30 sec. 
Results were analysed by Roche LC480 software v1.5 using absolute quantification by interpolation from the 
curves of standard from 1.0 × 102 to 1.0 × 109 copies/reaction and non-template control.
CD44 variants expression detection. To detect the expression of pan-CD44 and CD44v8-10 variants at 
the protein level, anti CD44 antibody (8E2) (Cell Signaling Technology, USA) and anti-CD44v9 antibody (RV3) 
(Cosmobio, Japan) were used. Briefly, cell were cultured on coverslip were fixed with paraformaldehyde and incu-
bated with 1:100 diluted antibody and then secondary antibody labelled with fluorescent dye. After washing with 
D-PBS, fluorescent images of the recorded by Axiovision Software (Carl Zeiss, Germany).
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Establishment of CD44 variant overexpression cell line. The open reading frames of CD44s and 
CD44v8-10 variants were amplified and cloned into GFP tagged pHRST lentiviral vector. These expression plas-
mids were propagated by transfecting HEK-293T cells, and harvesting lentiviral particle using Lenti-X concen-
trator (Clontech, Japan). CD44 negative MKN-28 gastric cancer cell lines were infected with each CD44s or 
CD44v8-10 expression lentivirus and stable transfectants were selected by GFP expression.
Synthesis of anti-CD44v9 antibody conjugates and assessment of its theranostic effi-
ciency. The antibody that recognized the extended stalk region containing variable exon 9 (RV3) was con-
jugated with N-hydroxysuccinimidyl (NHS)-functionalized ATTO680 (NHS-ATTO680; ATTO-TEC GmbH, 
Siegen, Germany) or MB (ATTO-MB2; ATTO-TEC GmbH, Siegen, Germany). In brief, anti-CD44v9 antibody 
(10 ug) was reacted with NHS-functionalized ATTO680 or MB (1 ug), in a phosphate buffered saline (PBS, 
10 mM, pH 7.4) at room temperature for 1 h in a light protected place with gentle shaking. Byproducts including 
unreacted ATTO680 or MB were removed from the mixture using a Sephadex G25 gel filtration column (PD 
MiniTrap G-25, GE Healthcare, USA), and then the products were concentrated by Amicon Ultra-0.5 mL centrif-
ugal filters (cut off: 50 kDa, EMD Millipore, USA). The resulting conjugate was kept at 4 °C before use.
Immunofluorescence images of patient tissues, anti-CD44v9-ATTO680 (0.1 μM ATTO680 equivalent) was 
diluted in 0.1 mL 1% BSA containing PBS buffer. Diluted anti-CD44v9-ATTO680 was added onto #68 patient 
stomach tissues sliced from frozen tissue and incubated for 1 h at R.T. After treatment, stained tissues were 
washed with 4 times and then optical images were obtained using Xenogen (ex. 660/20 nm, em. 710/40 nm, expo-
sure time: 1 sec).
For detecting of CD44v8-10 in stable cell lines, MKN-28, mock vector transfected MKN-28, MKN-28/CD44s 
and HDF for negative controls and MKN-28/CD44v8-10, SNU-638, KATO III for positive controls were seeded at 
a density of 5 × 104/well on a 4-well Lab-Tek II chambered cover glass (Thermo Fisher Scientific, USA) and incu-
bated overnight for cell attachment. CD44v9-ATTO680 conjugates were diluted in the medium (1.96 μg/0.5 mL, 
0.01 μM ATTO680 equivalent) and treated for 1 h. Fluorescence images were acquired using a confocal laser 
scanning microscope (Carl Zeiss LSM510 META, 40x, ex. 633 nm/ex. 679–754 nm).
In vitro photoimmunotherapy was performed in the mixed cell condition to evaluate whether 
anti-CD44v9-MB conjugate can selectively detect and damage the target cancer cells only. In the first set, 
CD44(−) HDF cells (5 × 103 cells) was mixed with MKN-28 transfected mock vector (5 × 103 cells) and 
seeded into 8-well Lab-Tek chamber. In the second set, CD44(−) MKN-28 and CD44v8-10(+) MKN-28 cells 
(5 × 103 cells, respectively) were mixed and seeded into 8-well Lab-Tek chamber. After incubating the cells for 
24 h for cell attachment, existing cell culture medium was replaced with fresh cell culture medium containing 
anti-CD44v9-MB conjugate (8.96 μg/0.3 mL, 0.2 μM MB equivalent), and the cells were treated for 1 h. Propidium 
iodide (PI, 3 μM) was co-treated to the cells to analyse damage of cell membranes. For photoimmunotherapy, the 
cells were irradiated with 633-nm laser for 7 min. The 633-nm He/Ne laser (5 mW) used in this test was the one 
equipped in confocal microscope to obtain fluorescence images in the light-irradiated region. Confocal fluores-
cence images were obtained using confocal microscopy (Carl Zeiss LSM 780, GFP: ex. 488 nm, em. 493–598 nm, 
PI: ex. 561 nm, em. 570–659 nm, MB: ex. 633 nm, em. 679–754 nm) before and after light irradiation.
Statistical analyses. The statistical significance of differences between groups was determined using 
Student’s t-test (paired). P-values less than 0.05 were considered statistically significant.
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